Therapeutic strategies for multiple myeloma (MM) have changed dramatically over the past
decade. Thus, the role of hematopoietic stem cell transplantation (HCT) must be considered …

A total of 228 patients with multiple myeloma (MM), 166 patients receiving autologous
transplantation (124 PBSC and 38 BM) and 66 patients receiving T-cell-depleted allogeneic …

We previously reported initial results in 102 multiple myeloma (MM) patients treated with
sequential high-dose melphalan and autologous hematopoietic cell transplantation followed …

We evaluated impact of melphalan dose on transplant outcomes for multiple myeloma.
Between 1995 and 2019 459 consecutive patients received a transplant; 69 (15%) received …

Multiple myeloma (MM) patients with high-risk cytogenetic abnormalities have inferior
survival outcomes and are underrepresented in clinical trials. There is scarce data on MM …

The Evolving Role of Transplantation in Multiple Myeloma: the Need for a Heterogeneous
Approach to a Heterogeneous Disease Page 1 564 Clinical Advances in Hematology & …

Background Allogeneic transplant in myeloma remains controversial. Patients and Methods
We performed a retrospective review of 76 patients in the Mayo Clinic database from 1993 to …

Background Despite routine evaluation of cytogenetics in myeloma, little is known regarding
the impact of high‐dose therapy (HDT) consolidation on overall survival (OS) or progression …

Within a prospective protocol, the incidence and impact of achievement of molecular
remission (mCR) and high-risk cytogenetics was investigated in 73 patients with multiple …

Allogeneic hematopoietic cell transplantation in multiple myeloma is limited by prior reports
of high treatment-related mortality. We analyzed outcomes after allogeneic hematopoietic …